Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus

Fig. 1

LDL-C levels and percentage of LDL-C reduction over time; data are number of patients (n) and percentage (%); grey bar = alirocumab, black bar = evolocumab. a Baseline LDL-C levels (n = 237), b LDL-C levels at month 3 (n = 227), c LDL-C levels at month 12 (n = 153); d % LDL-C reduction from baseline to month 3 (n = 227) e % LDL-C reduction from baseline to month 12 (n = 153)

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840